Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple dye replace major surgery for ovarian cancer staging?

NCT ID NCT07508306

Knowledge-focused Sponsor: Faculty of Medicine of Tunis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian cancer. About 30 women with stage I or II ovarian cancer will take part. If successful, this approach could reduce side effects like pain and longer recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient suspected with a FIGO Stage I or II ovarain cancer ( Based on MRI and scanner finding). Patients with planned for surgical complete stadification including pelvic and para-aortic lymphadenectomy.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age : aged 18 years-old or older * Diagnosis: Suspected Ovarian cancer on MRI finding (O-RADs 4 or 5) * FIGO stage: Stage I or II ( Based on MRI and scanner finding) * Planned Procedure: Patients with planned for surgical complete stadification including pelvic and para-aortic lymphadenectomy * Consent: Signing of the written informed consent after full information has been provided Exclusion Criteria: * Suspicious nodal involvement: Presence of suspicious lymph nodes on preoperative imaging (generally defined by a short-axis diameter ≥ 10 mm). * Disease extension: Radiological or intraoperative evidence of extra-pelvic metastases or peritoneal carcinomatosis. * Surgical history: History of lymphadenectomy, lymph node sampling, or major vascular surgery involving the aorta or the iliac vessels. * History of radiotherapy: Patients who have previously undergone pelvic or abdominal radiotherapy. * Allergies: Known allergy or adverse reaction to patent blue dyes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early stage ovarian tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early stage ovarian tumors Sentinel lymph node biopsy (SLNB)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maternity and neonatology center of Tunis

    RECRUITING

    La Rabta, 1007, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.